InBody Co., Ltd.
KKRX:04183047,050.00
KRW
-1,200.00
(-2.49%)
ISIN
KR7041830001
Return %
Stock
S&P 500
1Y
70.78
14.39
3Y
113.38
81.42
5Y
71.09
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Ki-Chul Cha
- Full Time Employees
- 370
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- InBody Building Seoul SL South Korea 06106
- IPO Date
- Dec 14, 2000
- Website
- inbody.com
- Similar Companies
- Business
- InBody Co., Ltd. manufactures and sells advanced electronic medical devices specializing in body composition analyzers. The company’s core products include body composition analyzers designed for clinical, sports, fitness, and home use; automatic sphygmomanometers (blood pressure monitors); stadiometers (height meters); body water analyzers; and body composition management software under the brands InBody and Lookin'Body. Its products serve diverse applications such as bariatrics, cardiology, diabetes management, frailty and aging assessment, ICU monitoring, lymphedema, nephrology, nutrition, oncology, sports medicine, rehabilitation, and physical therapy. InBody’s technology is validated by medical standards including FDA approval and is widely utilized by hospitals, clinics, fitness centers, and individual consumers globally. Founded in 1996 in Seoul, South Korea, the company operates through more than a dozen international subsidiaries including newly established units in North America and Malaysia, supporting its global reach in over 110 countries. Recent strategic initiatives include the launch of LookinBodyWeb, a cloud-based data software platform for body composition data management, and the introduction of the portable InBody270 device to facilitate professional on-the-go analysis. In 2025, InBody expanded its medical services division by establishing InBody BWA Inc. in North America with a focus on research-grade body water analysis and remote patient monitoring, aiming to integrate with healthcare insurance frameworks and expand its healthcare service offerings beyond devices. The company pursues strategic growth through direct distributor management and local sales strategies to stabilize and deepen market penetration, while maintaining a commitment to data-driven healthcare insights and service innovation. InBody continues evolving its business from a device manufacturer to a healthcare service provider by leveraging its extensive data accumulation of over 100 million data points to enhance remote health monitoring and community health integration. This transition is complemented by strong leadership emphasizing international market development, product quality, and organizational culture that encourages innovation and direct responsiveness to global market demands. The company remains headquartered in Seoul’s Gangnam district with approximately 1,100 employees worldwide. It is publicly listed on the KOSDAQ under ticker 041830.KQ. Overall, InBody operates within the healthcare equipment industry, focusing on body composition analysis technologies and expanding into medical and health data services to address broad medical and consumer health needs worldwide. Its recent expansions into cloud software, new device launches, and health service ecosystems mark significant advancements in its competitive positioning and strategic direction.